All News - Eli Lilly and Company
WEBRecent Press Releases. View All Press Releases. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Lilly expands manufacturing footprint in Ireland with $1.8 billion investment.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
News Release - Eli Lilly and Company
WEBAug 27, 2024 · News Release. Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity. Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity.
News Release - Eli Lilly and Company
WEBJul 14, 2023 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
News Release - Eli Lilly and Company
WEBNov 8, 2023 · News Release. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
News Release - Eli Lilly and Company
WEBApr 22, 2024 · INDIANAPOLIS and LINCOLNSHIRE, Ill., April 22, 2024 – Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.
News Release - Eli Lilly and Company
WEBApr 17, 2024 · Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
- Some results have been removed